Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Anacor Pharmaceuticals (NASDAQ:ANAC), a biopharmaceutical company focused on developing anti-fungal and anti-inflammatory medications, briefly dipped as much as 11% this morning following the Food and Drug Administration's approval of Kerydin as a treatment for onychomycosis of the toenails. Shares have since recovered and are now down just 1% as of this writing.

So what?: According to Anacor's early morning press release, the FDA has approved its topical solution known as Kerydin to treat a fungal infection of the toenail and nail bed that's found in approximately 35 million people in the U.S. According to Anacor's CEO Paul Berns "We expect to launch KERYDIN in the U.S., either alone or with a partner, as early as the end of this quarter." Based on a previous investor presentation from Anacor, the company believes Kerydin could have peak sales potential of beyond $1 billion.

Now what?: Normally we see a company move higher on an FDA approval, but two factors appear to be playing into today's drop. First, Anacor has rocketed higher in anticipation of this approval with shares rising from just $6 to yesterday's closing price of $16.74. In other words, it's not as if the market hasn't already factored in some of the optimism surrounding Kerydin. The other factor at work here is Berns' commentary about finding a partner. I suspect some investors are disappointed that the smaller Anacor has yet to find an established partner for its drug and they're worried about launch and execution risk. Personally, I'm excited for Anacor and its shareholders, but I share both of these aforementioned concerns. I'd stick to the sidelines and wait for Anacor to get a few quarters of sales under its belt before even considering the idea of chasing this stock any higher.

Kerydin may have plenty of potential, but this revolutionary product may leave it in the dust!  
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.